Business Context and Reporting Period
Company: StemCells, Inc. (formerly CytoTherapeutics, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2001
Business Overview: The company is a biotechnology firm focused on stem cell technology following a 1999 restructuring that abandoned its previous encapsulated cell therapy (ECT) program. The company has not commercialized any products and relies on external financing, grants, and investment income to fund operations. It is currently transitioning its headquarters and research facilities from Rhode Island to California.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenue (Grants) | $100,000 | $0 |
| Net Income (Loss) | $268,541 | ($1,794,258) |
| EPS (Basic) | $0.01 | ($0.09) |
| Operating Expenses | $2,641,119 | $1,798,732 |
| Cash and Equivalents (End of Period) | $4,499,158 | $4,502,209 |
| Short-term Investments | $8,412,650 | $16,356,334 |
| Total Assets | $21,506,661 | $29,794,979 |
| Accumulated Deficit | ($130,229,646) | ($130,498,187) |
Liquidity: The company held approximately $4.5 million in cash and $8.4 million in short-term restricted investments (Modex Therapeutics shares) as of March 31, 2001. Management expects existing resources to fund operations through December 2001.
Material Changes vs. Prior Period
- Profitability: The company reported a net income of $268,541 in Q1 2001, a significant turnaround from a net loss of $1.79 million in Q1 2000. This improvement was primarily driven by a one-time realized gain of $2,550,230 from the sale of Modex Therapeutics shares.
- Operating Expenses: Total operating expenses increased by approximately 47% to $2.64 million. Research and Development (R&D) expenses rose 81% to $1.64 million, and General and Administrative (G&A) expenses rose 52% to $996,862. These increases were attributed to hiring additional personnel (R&D staff grew from 11 to 19; G&A from 5 to 8) and leasing a larger facility in Palo Alto.
- Wind-down Costs: Wind-down expenses related to the former ECT program and Rhode Island facilities were $0 in Q1 2001, compared to $234,386 in Q1 2000. A reserve of $1.38 million remains for future wind-down costs.
- Investment Portfolio: The company sold a portion of its Modex Therapeutics holdings in January 2001. The remaining holdings were valued at $8.4 million at quarter-end but were subsequently sold in April 2001.
Outlook, Risks, and Unusual Items
- Unusual Items: The net income for the quarter is heavily influenced by the non-recurring gain on the sale of Modex shares. Without this gain, the company would have reported a significant operating loss.
- Subsequent Events: On April 30, 2001, the company sold its remaining Modex shares for approximately $5.2 million. Additionally, the company received $300,000 from Modex for the assignment of rights to future payments under a prior asset purchase agreement.
- Financing and Liquidity Risks: The company has no product revenue and expects to incur substantial losses in the future. It is dependent on external financing, grants, and the successful sublease or sale of its former Rhode Island facilities. Failure to dispose of these facilities could materially adversely affect liquidity.
- Grant Revenue: The company received a $100,000 grant from the NIH SBIR program in Q1 2001 and was awarded a two-year, $300,000/year grant in February 2001 for hepatitis research.
- Forward-Looking Statements: Management cautions that actual results may differ due to factors such as contamination, regulatory changes, competition, and the availability of capital.
Investor Verification Checklist
- Runway Validation: Verify if the $4.5 million cash balance and investment proceeds are sufficient to fund operations through the projected December 2001 date, given the high burn rate from increased R&D and G&A.
- Facility Disposal: Confirm the status of subleasing or selling the former Rhode Island facilities, as failure to do so poses a direct threat to liquidity.
- Revenue Sustainability: Assess the reliability of grant funding as a revenue source, noting the company has no commercial product sales.
- Capital Structure: Review the terms of the adjustable warrants issued to Millennium Partners, LP, which could lead to significant dilution of existing shareholders.
- One-Time Gains: Exclude the $2.55 million investment gain when analyzing the company's core operational performance and future profitability potential.